Status:
COMPLETED
Effect of CoVid-19 (CoronaVirusDisease-19) and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias
Lead Sponsor:
University Hospital, Antwerp
Collaborating Sponsors:
Medtronic
Conditions:
Covid19
Athletes Heart
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 can cause myocarditis, which can cause myocardial fibrosis. This has been shown to increase mortality and morbidity among athletes. Several efforts have been made to guide sports participatio...
Detailed Description
Baseline investigations will depend on the clinical presentation of the athlete. Three groups are identified: 1. Asymptomatic/mildly symptomatic: anosmia, ageusia, headache, mild fatigue, fever ≤3d, ...
Eligibility Criteria
Inclusion
- Athletes (professional or recreational but aiming to compete at a national or international level), performing mixed-type or endurance sports as defined by Pelliccia et al. who:
- have recovered from a proven (either by PCR (Polymerase Chain Reaction), serology or chest Computed Tomography) COVID-19 infection
- are more than 1-month post onset of symptoms or the first positive PCR and
- are willing to start (or are) exercising again
Exclusion
- known prior cardiac fibrosis
- known or newly diagnosed coronary artery disease
- allergy or contraindications for gadolinium contrast.
- unwillingness or impossibility to give informed consent
- Presence of edema on the CMR
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT04726150
Start Date
April 1 2021
End Date
October 31 2022
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Antwerp
Antwerp, Belgium, 2650